Oric Reports Enozertinib Phase 1b Results, Plans Phase 3 in 2027
Oric reported systemic and intracranial activity for enozertinib in Phase 1b and plans a global Phase 3 trial in the first half of 2027.
Oric Pharmaceuticals reported promising systemic and intracranial activity for enozertinib in Phase 1b and plans a global Phase 3 trial in the first half of 2027.Key Highlights:Original SEC Filing: Oric Pharmaceuticals, Inc. [ ORIC ] - 8-K - Oct. 23, 2026This is an AI-powered summary. It may contai…